SAMSUNG-ELECTRONICS
19.5.2020 09:02:14 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced Samsung ISOCELL GN1, a new 50-megapixel (Mp) image sensor with large 1.2μm-sized pixels. The ISOCELL GN1 is Samsung’s first image sensor to offer both Dual Pixel and Tetracell technologies. Thanks to the relatively larger pixel size, the GN1 brings image sensor performance to a new level with a combination of elevated light sensitivity for stellar low-light photos and DSLR-level auto-focus speeds, optimized for more dynamic picture-taking experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005376/en/
“With innovative pixel technologies, Samsung has been at the forefront of offering high-performance image sensors that closely cater to increasingly diversifying market needs. The ISOCELL GN1 is part of that commitment to deliver stunning images to consumers in any environment,” said Yongin Park, executive vice president of sensor business at Samsung Electronics. “We will continue to introduce image sensor solutions at the cutting-edge that will lead the next trends in mobile photography.”
Creating desirable images is an indispensable element for today’s smartphone users who are well accustomed to visually grasping and cherishing special moments, wherever they are. To address various imaging preferences of the users, some smartphone makers put more emphasis on extremely detailed images with ultra-high resolutions, while some choose bigger pixels for bright results in low-light environments. The new Samsung ISOCELL GN1 fulfills these multiple needs at once with Dual Pixel and Tetracell technologies.
The GN1 brings best-in-class auto-focusing with 100 million phase detection auto-focus (PDAF) agents. Samsung’s Dual Pixel technology places two photodiodes side-by-side within a single pixel that can receive light from different angles for phase detection. With all of the sensor’s active pixels working as auto-focusing agents, the GN1 can detect and focus onto a desired still or moving object from every corner in an instant, even in low-light conditions. When capturing images, a single pixel output is created by merging the outputs from the two photodiodes within the pixel. Samsung also provides a software algorithm that takes light information from each photodiode to produce image resolutions comparable to 100Mp.
For ultimate low-light photography, the GN1 adopts Tetracell technology, a pixel-merging technique that improves the pixels’ capacity to capture and process more light. By binning four pixel signals into one, Tetracell doubles the image sensor’s pixel size to 2.4μm and quadruples the light sensitivity to take brighter 12.5Mp photographs. With improved light sensitivity combined with a powerful auto-focusing solution, the GN1 is able to focus on an object quickly even in extreme low-light environment to deliver both brighter and sharper results.
In addition to Dual Pixel and Tetracell technologies, the GN1 comes with Smart-ISO that intelligently selects the optimal ISO, real-time HDR that captures the scene in multiple exposures simultaneously, and gyro-based electronic image stabilization (EIS) that takes sharp images and video even when in motion. For premium video quality, the image sensor supports video recording at up to 8K resolution at 30 frames-per-second (fps).
Samsung ISOCELL GN1 started mass production this month.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005376/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
